These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 38704133

  • 1. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
    Miller AL, Fehling SC, Vance RB, Chen D, Brown EJ, Hossain MI, Heard EO, Andrabi SA, Wang H, Yang ES, Buchsbaum DJ, van Waardenburg RCAM, Bellis SL, Yoon KJ.
    Cancer Lett; 2024 Jun 28; 592():216919. PubMed ID: 38704133
    [Abstract] [Full Text] [Related]

  • 2. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
    Miller AL, Fehling SC, Garcia PL, Gamblin TL, Council LN, van Waardenburg RCAM, Yang ES, Bradner JE, Yoon KJ.
    EBioMedicine; 2019 Jun 28; 44():419-430. PubMed ID: 31126889
    [Abstract] [Full Text] [Related]

  • 3. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G, Zhao J, Qin C, Zhang Z, Lin Y, Su Z.
    Cancer Lett; 2017 Jan 28; 385():65-74. PubMed ID: 27840243
    [Abstract] [Full Text] [Related]

  • 4. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
    Yamamoto K, Tateishi K, Kudo Y, Hoshikawa M, Tanaka M, Nakatsuka T, Fujiwara H, Miyabayashi K, Takahashi R, Tanaka Y, Ijichi H, Nakai Y, Isayama H, Morishita Y, Aoki T, Sakamoto Y, Hasegawa K, Kokudo N, Fukayama M, Koike K.
    Oncotarget; 2016 Sep 20; 7(38):61469-61484. PubMed ID: 27528027
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
    Zhang X, Zegar T, Weiser T, Hamdan FH, Berger BT, Lucas R, Balourdas DI, Ladigan S, Cheung PF, Liffers ST, Trajkovic-Arsic M, Scheffler B, Joerger AC, Hahn SA, Johnsen SA, Knapp S, Siveke JT.
    Int J Cancer; 2020 Nov 15; 147(10):2847-2861. PubMed ID: 32599645
    [Abstract] [Full Text] [Related]

  • 6. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH, Sui YN, Yan K, Wang LS, Wang F, Zhou JH.
    Oncol Rep; 2015 Apr 15; 33(4):1699-706. PubMed ID: 25647019
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X, Xie J, Lu X, Li H, Wen C, Huo Z, Xie J, Shi M, Tang X, Chen H, Peng C, Fang Y, Deng X, Shen B.
    Cancer Lett; 2017 Jul 28; 399():1-9. PubMed ID: 28428074
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X, Chen W, Xue F, Liang C, Chen BW, Zhou Y, Wen L, Hu L, Shen J, Bai X, Liang T.
    Oncotarget; 2015 Sep 22; 6(28):26230-41. PubMed ID: 26213847
    [Abstract] [Full Text] [Related]

  • 11. Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
    Knoll L, Hamm J, Stroebel P, Jovan T, Goetze R, Singh S, Hessmann E, Ellenrieder V, Ammer-Herrmenau C, Neesse A.
    Neoplasia; 2024 Jul 22; 53():101002. PubMed ID: 38744194
    [Abstract] [Full Text] [Related]

  • 12. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
    Ju HQ, Zhuang ZN, Li H, Tian T, Lu YX, Fan XQ, Zhou HJ, Mo HY, Sheng H, Chiao PJ, Xu RH.
    Cancer Lett; 2016 Aug 28; 379(1):1-11. PubMed ID: 27233476
    [Abstract] [Full Text] [Related]

  • 13. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC.
    Huang W, Hu X, He X, Pan D, Huang Z, Gu Z, Huang G, Wang P, Cui C, Fan Y.
    Drug Resist Updat; 2024 May 28; 74():101079. PubMed ID: 38518727
    [Abstract] [Full Text] [Related]

  • 14. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, Zhuo Q, Ji S, Yu X, Xu X, Qin Y, Li Z.
    Cancer Lett; 2024 Oct 10; 602():217197. PubMed ID: 39216548
    [Abstract] [Full Text] [Related]

  • 15. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H, Gao W, Li X, Yu L, Luo D, Liu Y, Yu X.
    Pancreatology; 2021 Apr 10; 21(3):589-598. PubMed ID: 33579599
    [Abstract] [Full Text] [Related]

  • 16. Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
    Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE.
    J Exp Clin Cancer Res; 2013 Mar 06; 32(1):12. PubMed ID: 23497499
    [Abstract] [Full Text] [Related]

  • 17. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S, Krantz SB, Barron MR, Shields MA, Heiferman MJ, Grippo PJ, Bentrem DJ, Munshi HG.
    Cancer Res; 2011 Feb 01; 71(3):1019-28. PubMed ID: 21148071
    [Abstract] [Full Text] [Related]

  • 18. Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.
    Shah A, Jahan R, Kisling SG, Atri P, Natarajan G, Nallasamy P, Cox JL, Macha MA, Sheikh IA, Ponnusamy MP, Kumar S, Batra SK.
    Cancer Lett; 2024 Aug 28; 598():217097. PubMed ID: 38964729
    [Abstract] [Full Text] [Related]

  • 19. YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine.
    Li Y, Wang X, Yu H, Cao J, Xie J, Zhou J, Feng Z, Chen W.
    Mol Carcinog; 2024 Oct 28; 63(10):1953-1966. PubMed ID: 39016677
    [Abstract] [Full Text] [Related]

  • 20. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance.
    Ma MJ, Shi YH, Liu ZD, Zhu YQ, Zhao GY, Ye JY, Li FX, Huang XT, Wang XY, Wang JQ, Xu QC, Yin XY.
    Oncogene; 2024 Jul 28; 43(31):2405-2420. PubMed ID: 38914663
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.